Alivus Life Sciences Ltd
NSE: ALIVUS · Pharma - CDMO/API
Snapshot
Unlock Alivus Life Sciences Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Glenmark Life Sciences Limited is a research-driven developer and manufacturer of high-quality active pharmaceutical ingredients (APIs) for chronic therapeutic areas. The company also provides contract development and manufacturing services to global pharmaceutical firms.
Business Model
The company generates revenue through the sale of non-commoditized APIs across cardiovascular, central nervous system, diabetes, and pain management segments. Additionally, it leverages its manufacturing capabilities to provide contract development and manufacturing services to multinational clients.
Growth Outlook
Growth is driven by the expansion of its API portfolio in chronic therapeutic areas and the strengthening of its contract development and manufacturing services partnerships. The company continues to leverage its global export footprint to capture demand in regulated markets.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality audits and inspections by international regulatory bodies like the USFDA.
- Customer Concentration. A significant portion of revenue is derived from a limited number of multinational pharmaceutical clients, making the company vulnerable to changes in their procurement strategies.
- Raw Material Price Volatility. Fluctuations in the costs of key starting materials and intermediates can impact profit margins due to the company's reliance on global supply chains.
- Geopolitical and Currency Risk. As an export-oriented business, the company is exposed to currency fluctuations and potential trade barriers in its key markets of Europe, North America, and Japan.
Start your research today
Unlock AI insights, financials, peers and live data on Alivus Life Sciences Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,590 Cr
TTM · standalone
NET PROFIT
₹603 Cr
TTM · standalone
EPS
₹49.12
TTM · standalone
RETURN ON EQUITY
19.6%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
25.1%
TTM · standalone
P/E
27.8x
Q1 FY27 · standalone
EV/EBITDA
18.4x
Q1 FY27 · standalone
EBITDA MARGIN
35.1%
TTM · standalone
NET PROFIT MARGIN
25.0%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharma - CDMO/API
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Alivus Life Sciences LtdALIVUS | ₹16,770 Cr | 27.82 | 18.42 | 7.9% | 35.1% | 19.6% | 25.1% | +47.1% |
Viyash Scientific LtdVIYASH | ₹11,614 Cr | 81.80 | 23.42 | 70.4% | 19.1% | 8.4% | 13.0% | +50.1% |
Jubilant Ingrevia Ltd.JUBLINGREA | ₹10,836 Cr | 34.82 | 17.24 | 11.0% | 14.3% | 10.2% | 12.4% | -7.0% |
As of Q1 FY27
Financials
Alivus Life Sciences Ltd
NSE: ALIVUS · Pharma - CDMO/API
Snapshot
Unlock Alivus Life Sciences Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Glenmark Life Sciences Limited is a research-driven developer and manufacturer of high-quality active pharmaceutical ingredients (APIs) for chronic therapeutic areas. The company also provides contract development and manufacturing services to global pharmaceutical firms.
Business Model
The company generates revenue through the sale of non-commoditized APIs across cardiovascular, central nervous system, diabetes, and pain management segments. Additionally, it leverages its manufacturing capabilities to provide contract development and manufacturing services to multinational clients.
Growth Outlook
Growth is driven by the expansion of its API portfolio in chronic therapeutic areas and the strengthening of its contract development and manufacturing services partnerships. The company continues to leverage its global export footprint to capture demand in regulated markets.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality audits and inspections by international regulatory bodies like the USFDA.
- Customer Concentration. A significant portion of revenue is derived from a limited number of multinational pharmaceutical clients, making the company vulnerable to changes in their procurement strategies.
- Raw Material Price Volatility. Fluctuations in the costs of key starting materials and intermediates can impact profit margins due to the company's reliance on global supply chains.
- Geopolitical and Currency Risk. As an export-oriented business, the company is exposed to currency fluctuations and potential trade barriers in its key markets of Europe, North America, and Japan.
Start your research today
Unlock AI insights, financials, peers and live data on Alivus Life Sciences Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,590 Cr
TTM · standalone
NET PROFIT
₹603 Cr
TTM · standalone
EPS
₹49.12
TTM · standalone
RETURN ON EQUITY
19.6%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
25.1%
TTM · standalone
P/E
27.8x
Q1 FY27 · standalone
EV/EBITDA
18.4x
Q1 FY27 · standalone
EBITDA MARGIN
35.1%
TTM · standalone
NET PROFIT MARGIN
25.0%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharma - CDMO/API
As of Q1 FY27